AstraZeneca completes divestment of Imdur

RNS Number : 9466W
AstraZeneca PLC
03 May 2016
 

ASTRAZENECA COMPLETES DIVESTMENT OF IMDUR

TO CHINA MEDICAL SYSTEM HOLDINGS

 

AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.

Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries

 

 

 


Neil Burrows

UK/Global

+44 20 7604 8032

Vanessa Rhodes

 

UK/Global

+44 20 7604 8037

Karen Birmingham

UK/Global

+44 20 7604 8120

Jacob Lund

 

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Enquiries



UK



Thomas Kudsk Larsen

 


+44 7818 524185

Eugenia Litz

RIA

 

+44 7884 735627

Nick Stone

CVMD

 

+44 7717 618834

Craig Marks

Finance

+44 7881 615764

Christer Gruvris

 

Consensus Forecasts

+44 7827 836825

US



Lindsey Trickett

  Oncology, ING

+1 240 543 7970

Mitch Chan

  Oncology

+1 240 477 3771

Dial / Toll-Free


+1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal





03 May 2016

 

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBIGDUBBGBGLD

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings